Last reviewed · How we verify
NCT06773429
Estradiol and Brain Age
trial testing E2 Valerate in Estradiol (E2) Vs. Placebo (PLAC) in 32 participants. Completed in 31 July 2019.
31 July 2019
Quick facts
| Lead sponsor | International Research Training Group 2804 |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 32 |
| Start date | 1 August 2018 |
| Primary completion | 31 July 2019 |
| Estimated completion | 31 July 2019 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- E2 Valerate — full drug profile →
- Placebo
Conditions studied
- Estradiol (E2) Vs. Placebo (PLAC) — all drugs for Estradiol (E2) Vs. Placebo (PLAC) →
- Estradiol — all drugs for Estradiol →
Sponsor
International Research Training Group 2804 — full company profile →
Who can join
Adults 19 to 32, female only, with Estradiol (E2) Vs. Placebo (PLAC) or Estradiol. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The ovarian hormone estradiol (E2) is suspected to have a neuroprotective effect on the brain. Further, it is associated with mental health and brain plasticity, function and connectivity. During the menstrual cycle, women experience fluctuation of E2. This is closely associate with neuroplasticity in regions with high estradiol receptor density, such as the hippocampus, anterior cingulate cortex, amygdala, hypothalamus, or the striatum. In the current study we are interested on the effects of E2 on the brain age, indicated by the comparison between the chronological age and the predicted brain age. In a double-blind within-subject study design, naturally cycling females during their follicular menstrual cycle phase (when their endogenous ovarian hormone levels are low) were either administered estradiol valerate (E2) or a placebo (PLAC) to rapidly increase E2 levels independent of other cycling ovarian hormones. Structural brain scans were assessed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06773429
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other International Research Training Group 2804 trials
Trials by the same sponsor.
- NCT06711809 — Sleep, Oxytocin and Reward Processing in Women in the Postpartum Phase · not yet recruiting
- NCT06426459 — Social Media Usage in Adolescent Girls · not yet recruiting
- NCT06346457 — Breast Cancer & Antiestrogenic Therapy & Brain · unknown
- NCT06222749 — Oxytocin and Reward Processing in Women · NA · recruiting
- NCT06312033 — Estradiol's Effect on Brain Volume and Connectivity · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06773429 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by International Research Training Group 2804
- Last refreshed: 30 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06773429.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing